Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Interest Income

Income earned on cash, deposits, and investments held by the company.

Atai Beckley Inc.NASDAQ: ATAI

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income dips below year-ago levels

Q2 FY2026 interest income of $79K fell 68.1% year over year, behind the +52.6% change in trailing-twelve-month interest income. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +39.2% a year.

Context

  • Interest income amounted to 36.1% of revenue in FY2025, down 216.5 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -68.1% toward the trailing-twelve-month pace of +52.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$79K+1.3% QoQ
Last fiscal yearDec 2025
$1.48M+90.0% YoY
LTMJun 2026
$1.2M+52.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.1%——
1 year+90.0%——
3-year CAGR+39.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
1.48M USD
Year-over-year change
+90.0%
4-year CAGR
+63.9%

Interest Income vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.6% is the 3rd highest of 11, against a peer median of -14.9%.
  • Interest income amounts to 26.8% of revenue for ATAI, versus a peer median of 139.3%.
ATAI Competitors
Interest Income for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$26.73M USD+71.0%+141.5%1404.0%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$24.58M USD-23.6%+45.4%237.5%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$24.38M USD-6.3%+57.0%11.2%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$21.9M USD+44.9%+142.1%—
NKTRNektar TherapeuticsLTM Jun 2026$19.18M USD+70.9%+15.5%35.1%
IMTXImmatics N.V.LTM Mar 2026€15.3M EUR-36.7%+90.7%41.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$12.37M USD+48.5%+29.4%—
INBXInhibrx Biosciences, Inc.LTM Mar 2026$6.23M USD-37.5%-22.3%479.0%
ATAIAtai Beckley Inc.LTM Jun 2026$1.2M USD+52.6%+39.2%26.8%
SANASana Biotechnology, Inc.LTM Mar 2026$962K USD-88.6%+0.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding ATAI) —-14.9%+45.4%139.3%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.